A phase II non-randomized study of DOXIL [doxorubicin liposomal] consolidation treatment for ovarian cancer, cancer of the Fallopian tube or peritoneal carcinoma

Trial Profile

A phase II non-randomized study of DOXIL [doxorubicin liposomal] consolidation treatment for ovarian cancer, cancer of the Fallopian tube or peritoneal carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2011

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Oct 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
    • 07 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Feb 2008 The expected completion date for this trial is now 1 Apr 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top